Abeona Therapeutics Reports Third Quarter Financial Results
November 15, 2021 07:45 ET
|
Abeona Therapeutics Inc.
Phase 3 VIITAL™ study on track to complete enrollment in first quarter 2022 with final patients identified and under screening Added gene therapy and biopharmaceutical industry veterans to regulatory...
Abeona Therapeutics to Present at Jefferies Gene Therapy/Editing Summit
October 21, 2021 07:30 ET
|
Abeona Therapeutics Inc.
NEW YORK and CLEVELAND, Oct. 21, 2021 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO), a fully-integrated leader in gene and cell therapy, today announced that Vish Seshadri, Ph.D.,...
Abeona Therapeutics Announces Clinical Data Presentations at Upcoming Scientific Congresses
October 13, 2021 07:30 ET
|
Abeona Therapeutics Inc.
NEW YORK and CLEVELAND, Oct. 13, 2021 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO), a fully-integrated leader in gene and cell therapy, today announced two presentations of previously...
Abeona Therapeutics Appoints Gene Therapy Quality Leader Jon Voss as Vice President, Head of Quality
October 12, 2021 07:30 ET
|
Abeona Therapeutics Inc.
NEW YORK and CLEVELAND, Oct. 12, 2021 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO), a fully-integrated leader in gene and cell therapy, today announced the appointment of Jon Voss as...
Abeona Announces New Chairman, Executive Leadership Promotions and Key Talent Additions for Final Push Towards Two Biologics License Application (BLA) Filings
September 21, 2021 16:01 ET
|
Abeona Therapeutics Inc.
Steven H. Rouhandeh to retire as Chairman of the Board; Michael Amoroso appointed Chairman of the Board Vishwas Seshadri, Ph.D., M.B.A. to become Chief Executive Officer Brendan M. O’Malley,...
Abeona Therapeutics to Present at Upcoming Investor Conferences
September 07, 2021 07:30 ET
|
Abeona Therapeutics Inc.
NEW YORK and CLEVELAND, Sept. 07, 2021 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO), a fully-integrated leader in gene and cell therapy, today announced that members of the company’s...
Abeona Therapeutics Appoints Edward Carr as Chief Financial Officer
August 10, 2021 07:30 ET
|
Abeona Therapeutics Inc.
NEW YORK and CLEVELAND, Aug. 10, 2021 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO), a fully-integrated leader in gene and cell therapy, today announced the appointment of Edward Carr...
Abeona Therapeutics Reports Second Quarter Financial Results
July 28, 2021 16:01 ET
|
Abeona Therapeutics Inc.
Second clinical trial site activated in EB-101 pivotal Phase 3 VIITAL™ study Successful Type B meeting with U.S. FDA; Transpher A study will serve as the pivotal study for ABO-102 in MPS IIIA;...
Abeona Therapeutics Announces Successful Type B Meeting with U.S. FDA for ABO-102 AAV-based Gene Therapy in Sanfilippo Syndrome Type A (MPS IIIA)
July 28, 2021 07:30 ET
|
Abeona Therapeutics Inc.
Transpher A; pivotal study for intended registration of ABO-102 for MPS IIIA disease Alignment with FDA on primary study endpoint NEW YORK and CLEVELAND, July 28, 2021 (GLOBE NEWSWIRE) -- Abeona...
Abeona Therapeutics Announces New MRI Data Showing Increased Brain Volume in Young Patients with Sanfilippo Syndrome Type A (MPS IIIA) After Treatment with ABO-102 Gene Therapy
July 26, 2021 07:30 ET
|
Abeona Therapeutics Inc.
NEW YORK and CLEVELAND, July 26, 2021 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO), a fully-integrated leader in gene therapy, today announced magnetic resonance imaging (MRI) data...